Coexistence of antinucleosome and anti-double-stranded DNA antibodies is associated with severe systemic lupus erythematosus in Tunisian patients.

Abstract

Introduction: We sought to compare clinical features among distinct antibody profiles defined by the presence or absence of antinucleosome (anti-NCS) and anti-double-stranded DNA (anti-dsDNA) antibodies in Tunisian patients with systemic lupus erythematosus (SLE).

Methods: The study enrolled 131 patients with SLE meeting at least 4 American College of Rheumatology or SLICC criteria. Participants were recruited from the Department of Internal Medicine and Rheumatology at the university teaching hospital of Monastir between January 2000 and December 2022. The patients were divided into 4 groups: Group 1 with neither anti-dsDNA nor anti-NCS; Group 2 with anti-dsDNA and no anti-NCS; Group 3 with anti-NCS lacking anti-dsDNA; and Group 4 with both anti-NCS and anti-dsDNA.

Results: The mean (SD) age at the time of diagnosis for the 131 participants with SLE was 38.7 (15.1) years; the ratio of female to male individuals was 7.2. Thirty-four (26%) patients were positive for anti-NCS and anti-dsDNA (group 4: antinuclear antibody pattern AC-1, 72%; pattern AC-5, 16%), and 30 (22.9%) were positive for anti-NCS and negative for anti-dsDNA (group3: pattern AC-1, 53.6%; pattern AC-5, 32.1%). The group 3 patients showed higher peripheral neuropsychiatric SLE (P =.034) and lower rates of disease activity (P =.01). The comparison between the 4 groups showed that group 4 patients had the highest frequency of lupus nephritis (P ≤.001) and the highest rate disease activity (P =.013).

Discussion: Patients with both anti-NCS and anti-dsDNA at the time of diagnosis are likely to have severe SLE, while anti-NCS was associated with nonsevere disease in patients with SLE who lack anti-dsDNA.